$92.7M
+$92.7M this year1 filing since 2026 · latest Equity filed
Georgiamune is a clinical-stage immunotherapeutics company in Gaithersburg, Maryland, founded by Dr. Samir Khleif to reprogram immune signaling pathways so the immune system attacks cancer or stands down in autoimmune disease. Its pipeline pairs dual-functioning monoclonal antibodies with immune-reprogramming small molecules, led by GIM-122, GIM-531 and GIM-407. The company cleared an FDA IND for GIM-122 and raised a $75M Series A in 2023, and moved three assets into clinical trials in 2024. Additional discovery and IND-enabling programs (GIM-616, GIM-710 and others) remain undisclosed.
What sets it apart
Targets immune signaling reprogramming rather than a single checkpoint, with dual-functioning antibodies aimed at overcoming resistance to existing immunotherapy and paired small molecules that either inhibit or activate T-regulatory cells depending on whether the goal is oncology or autoimmunity.
A first-in-class dual-functioning monoclonal antibody developed to overcome resistance to immunotherapy in cancer patients; it received FDA clearance of its Investigational New Drug application in 2023.
